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ABSTRACT
Pancreatic adenocarcinoma is currently the fourth leading cause for cancerrelated mortality. Malignant progression of pancreatic cancer depends not only on
rapid proliferation of tumor cells but also on increased cell motility. In this study, we
showed that increased PHLPP expression significantly reduced the rate of migration
in pancreatic ductal adenocarcinoma (PDAC) cells whereas knockdown of PHLPP had
the opposite effect. In addition, cell motility at the individual cell level was negatively
regulated by PHLPP as determined using time-lapse imaging. Interestingly, the
expression of β1 and β4 integrin proteins were decreased in PHLPP overexpressing
cells and increased in PHLPP knockdown cells whereas the mRNA levels of integrin were
not altered by changes in PHLPP expression. In determining the molecular mechanism
underlying PHLPP-mediated regulation of integrin expression, we found that inhibition
of lysosome activity rescued integrin expression in PHLPP overexpressing cells, thus
suggesting that PHLPP negatively controls cell motility by inhibiting Akt activity to
promote lysosome-dependent degradation of integrins. Functionally, the increased
cell migration observed in PHLPP knockdown cells was effectively blocked by the
neutralizing antibodies against β1 or β4 integrin. Taken together, our study identified
a tumor suppressor role of PHLPP in suppressing cell motility by negatively regulating
integrin expression in pancreatic cancer cells.

Key mutations in oncogenes such as KRAS with deactivation
of tumor suppressor genes SMAD4 and CDKN2A/INK4A
have been implicated in the development and progression
of pancreatic cancer [3, 4]. In addition, it has been shown
that overexpression of integrin α6β4 promotes migration
and invasion of pancreatic cancer cells and is associated
with the progression of PDAC [5, 6]. Integrins are known
to contribute to tumor progression and metastasis by directly
activating a number of oncogenic signaling pathways,
including PI3K/Akt and RAS/RAF pathways, in various
types of cancer [7, 8]. However, the molecular mechanism by
which the expression of integrin proteins is regulated remains
elusive in pancreatic cancer cells.
PHLPP (PH domain leucine-rich repeat protein
phosphatase) belongs to a novel family of Ser/Thr protein
phosphatases. There are two isoforms, PHLPP1 and
PHLPP2, identified in this family [9–12]. Both PHLPP
isoforms were first discovered as the phosphatases for

INTRODUCTION
Pancreatic adenocarcinoma is the fourth leading
cause of cancer related deaths in the United States,
despite being the ninth most diagnosed cancer in men
and the eleventh in women. PDAC arises from the
exocrine portion of the pancreas and accounts for 95% of
all pancreatic adenocarcinoma [1]. PDAC has a dismal
5-year survival rate of 4% and a median survival span of
6 months from the point of diagnosis, and it has a high
rate of chemotherapy and radiation resistance [1]. Thus,
a better understanding of the molecular events leading
to cancer progression is needed in order to improve the
treatment and prognosis of PDAC patients.
Accumulation of genetic mutations in oncogenes and
tumor suppressors lead to the development of pre-malignant
lesions which eventually through genetic instability give rise
to carcinoma within the pancreatic ductal epithelium [2].
www.impactjournals.com/oncotarget
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Akt that directly dephosphorylate the hydrophobic motif
Ser473 site and inactivate the kinase [9, 10]. Moreover, it
has been shown that PHLPP dephosphorylates Ser338, a
key activation site on RAF1, and inhibits the downstream
signaling through RAF/MEK/ERK in colon cancer cells
[13]. Therefore, PHLPP may exert its tumor suppressor
function by negatively regulating both the PI3K/Akt and
RAS/RAF pathways. Recently, Nitsche et al discovered
that there is a stage-dependent downregulation of PHLPP
in pancreatic cancer patient specimens, thus suggesting a
tumor suppressor role of PHLPP in pancreatic cancer [14].
However, it remains unknown whether loss of PHLPP
expression promotes cancer cell migration in pancreatic
cancer.
In this study, we determined the role of PHLPP
in regulating cell migration and motility in pancreatic
cancer cells. We identified a functional connection
between PHLPP expression and integrin function.
Results from our study revealed that PHLPP-loss
increases cell motility by upregulating integrin
expression and inducing EMT. Furthermore, we found
that PHLPP negatively controls integrin expression by

promoting lysosome-mediated degradation of integrin
via inhibition of Akt.

RESULTS
PHLPP negatively regulates the activity of Akt
and MEK/ERK in pancreatic cells
To determine if PHLPP serves as a tumor
suppressor in human pancreatic cancer, we established
stable cell lines overexpressing PHLPP1 or PHLPP2
in Panc-1 cells, which express very low levels of
endogenous PHLPPs. The PHLPP1 gene potentially
encodes two differentially spliced variants, PHLPP1α
and PHLPP1β [11]. Since the longer transcript of
PHLPP1, PHLPP1β, is the predominant form expressed
endogenously in all pancreatic cell lines examined, we
used PHLPP1β in our study. We first determined the
effect of PHLPP overexpression on cell signaling. As
shown in Figure 1, both Akt and MEK/ERK activity
were downregulated in PHLPP overexpressing cells
compared to control cells as indicated by decreased

Figure 1: Overexpression of PHLPP isoforms inhibit PI3K/Akt and MEK/ERK signaling. A. Stable control, HA-PHLPP1β
or HA-PHLPP2 overexpressing Panc-1 cells were generated using retrovirus-mediated infection. The cell lysates were prepared and
analyzed for phosphorylation and total protein expression by immunoblotting. B. Relative phosphorylation for p-Akt, p-MEK, p-ERK
were calculated and normalized to those of total Akt, MEK and ERK, respectively. The level in control cells was set to 1. Data represent the
mean ± SEM (n = 3, * p<0.05 by two-sample t-tests).
www.impactjournals.com/oncotarget
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phosphorylation of Akt, MEK, and ERK. Next, to
determine the effect of endogenous PHLPP on Akt
and MEK/ERK signaling, PHLPP was silenced in
ASPC-1 cells, which express relatively higher levels of
endogenous PHLPPs, using lentiviral-mediated RNAi.
Immunoblotting results revealed that phosphorylation
of Akt, MEK, and ERK was significantly elevated
when PHLPP expression was knocked down
(Figure 2). Consistent with previous reports on the
tumor suppressor function of PHLPP in other cancer
types [13, 15–18], our results here provide the initial
evidence that PHLPP is capable of inhibiting both Akt
and MEK/ERK signaling in pancreatic cancer cells.

expression of EMT markers in PHLPP overexpressing
Panc-1 and PHLPP knockdown ASPC-1 cells. As
shown in Figure 3A, PHLPP overexpression markedly
increased the expression of E-cadherin, an epithelial
cell marker, and decreased the expression of vimentin,
a mesenchymal cell marker. Conversely, knockdown
of either PHLPP isoform decreased E-cadherin
whereas increased vimentin expression (Figure 3A),
suggesting that PHLPP downregualtion promotes EMT
in pancreatic cancer cells. Furthermore, we found that
PHLPP overexpressing cells migrated significantly
slower than the control cells as determined by
Transwell migration assays (Figure 3B). In contrast,
knockdown of PHLPP significantly enhanced the
ability of pancreatic cancer cells to migrate in response
to HGF. Similar results were obtained when using
IGF-1 and collagen were used as chemoattractants
(Supplementary Figure S1).
We next determined the effect of PHLPP on
modulating cell motility at the single cell level. To
this end, PHLPP overexpressing Panc-1 and PHLPP
knockdown ASPC-1 cells were subjected to cell

PHLPP negatively regulates cell migration in
pancreatic cancer cells
Previous studies of PHLPP expression in
colorectal cancer cells showed an enhanced ability
for PHLPP knockdown cells to migrate and transition
into EMT [13]. To test if PHLPP regulates cell motility
in pancreatic cancer cells, we first examined the

Figure 2: Loss of PHLPP expression enhances PI3K/Akt and MEK/ERK signaling. A. Stable control (sh-Con) and PHLPP
knockdown (sh-PHLPP1 and sh-PHLPP2) ASPC-1 cells were generated using lentivirus-mediated RNAi. The cell lysates were analyzed for
phosphorylation and total protein expression by immunoblotting. B. Relative phosphorylation for p-Akt, p-MEK, p-ERK were calculated
and normalized to those of total Akt, MEK and ERK, respectively. The level in control cells was set to 1. Data represent the mean ± SEM
(n = 3, * p<0.05 by two-sample t-tests).
www.impactjournals.com/oncotarget
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tracking experiments to monitor the cell movement
in real time. We found that overexpression of PHLPP
resulted in a significant decrease in cell motility when
compared to the control cells (Figure 4A), whereas
PHLPP knockdown cells were considerably more
motile (Figure 4D). The velocity and average distances

traveled were significantly decreased in PHLPP
overexpressing cells (Figure 4B–4C) while significantly
increased in PHLPP knockdown cells (Figure 4E–4F).
Taken together, we have identified a role of PHLPP
in inhibiting EMT and cell motility in pancreatic
cancer cells.

Figure 3: Knockdown of PHLPP expression induces EMT and promotes cell migration. A. Cell lysates were prepared from

stable control and PHLPP overexpressing Panc-1 as well as PHLPP knockdown ASPC-1 cells. The expression levels of E-cadherin and
vimentin were analyzed using immunoblotting. B. Stable control and PHLPP overexpressing Panc-1 cells were subjected to Transwell
migration assays using HGF and laminin as chemoattractants. C. Stable control and PHLPP knockdown ASPC-1 cells were subjected to
Transwell migration assays using HGF and laminin as chemoattractants. The inserts shown in (B) and (C) were representative images of
cells migrated in the Transwell assays. Each experiment was done in duplicates and three independent experiments were averaged and
expressed as mean ± SEM (* p<0.05 by two-sample t-tests compared to the control cells).
www.impactjournals.com/oncotarget
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Figure 4: PHLPP controls cell motility at the single cell level. A. Migration patterns of stable control and PHLPP overexpressing

Panc-1 cells on laminin coated plates using HGF as the chemoattractant. The trajectories of 12 randomly chosen cells for each cell line were
plotted in the graphs. B–C. The average distance traveled (B) and the relative velocity (C) of 12 stable control and PHLPP overexpressing
Panc-1 cells during 6 hours of migration. Data represent mean ± SD (n = 12 cells/line, * p<0.05 by two-sample t-tests). D. Migration
patterns of stable control and PHLPP knockdown ASPC-1 cells on laminin coated plates using HGF as the chemoattractant. The trajectories
of 12 randomly chosen cells for each cell line were plotted in the graphs. E–F. The average distance traveled (E) and the relative velocity
(F) of 12 stable control and PHLPP knockdown ASPC-1 cells during 6 hours of migration are shown. Data represent mean ± SEM (n = 12
cells/line, * p<0.05 by two-sample t-tests).
www.impactjournals.com/oncotarget
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PHLPP inhibits the invasive growth of
pancreatic cancer cells in 3D culture

However, the formation of membrane protrusions was
completed blocked in PHLPP overexpressing cells and the
size of cell clusters was significantly decreased (Figure 5C).
In addition, TIRF images of control Panc-1 cells showed
the formation of both stress fibers and long filamentous
extensions at the basolateral membrane surrounding
the entire cell whereas very few actin stress fibers were
observed in PHLPP overexpressing cells (Supplementary
Figure S2). Although no clear membrane protrusions were
observed in ASPC-1 cells grown in Matrigel, PHLPP
knockdown cells formed significantly larger globular
clusters compared to the control cells, suggesting that
PHLPP-loss increases the invasive growth ability of
pancreatic cancer cells (Figure 6A–6C).

To further determine the effect of PHLPP on invasive
growth of pancreatic cancer cells, we used 3D cell culture
systems as they closely mimic the cancer microenvironment
and they provide a better opportunity to explore the effects
of oncogenes and tumor suppressors on modulating
morphogenesis as well as invasive growth [19, 20]. Both
PHLPP overexpressing Panc-1 and PHLPP knockdown
ASPC-1 cells were seeded into Matrigel and allowed to
grow for up to 7 days. The control Panc-1 cells grew into
large multi-globular clusters with spikes of membrane
protrusions extending into Matrigel (Figure 5A–5B).

Figure 5: PHLPP inhibits the invasive phenotype of pancreatic cancer cells grown in 3D culture. A–B. Stable control and

PHLPP overexpressing Panc-1 cells were seeded in Matrigel and allowed to grow for 7 days. On the 3rd day (A) and the 7th day (B) after
seeding phase-contrast images were taken with the 10X objective on using an inverted Nikon microscope. The boxed regions were enlarged
and shown next to the original images. Scale bars, 100 μm. C. The size of cell clusters at day 7 was measured and analyzed using Nikon
Element AR software. Data represent mean ± SEM (n = 18 cells/line, * p<0.05 by two-sample t-tests).
www.impactjournals.com/oncotarget
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PHLPP regulates the expression of integrin in
pancreatic cancer cells

both β4 and β1 integrin were significantly reduced in
PHLPP overexpressing Panc-1 cells and increased in
the PHLPP knockdown ASPC-1 cells (Figure 7A–7C).
To further determine if PHLPP-mediated regulation
of β4 and β1 integrin expression is controlled at the
transcriptional level, total RNAs were isolated from
PHLPP overexpressing Panc-1 and PHLPP knockdown

Previous studies have shown that increased β4
integrin expression is associated with pancreatic cancer
progression [5]. Interestingly, when examining the
expression of β integrin, we found that expression of

Figure 6: Knockdown of PHLPP promotes the invasive growth of pancreatic cancer cells in 3D culture. A–B. Stable
control and PHLPP knockdown ASPC-1 cells were seeded in Matrigel and allowed to grow for 7 days. On the 5th day (A) and the 7th
day (B) after seeding phase-contrast images were taken with the 10X objective on using an inverted Nikon microscope. Scale bars, 100
μm. C. The size of cell clusters at day 7 was measured and analyzed using Nikon Element AR software. Data represent mean ± SEM
(n = 18 cells/line, * p<0.05 by two-sample t-tests).
www.impactjournals.com/oncotarget
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Figure 7: PHLPP regulates integrin protein expression. A. Cell lysates prepared from PHLPP overexpressing Panc-1 and PHLPP
knockdown ASPC-1 cells were analyzed for the expression of β1 and β4 integrin and tubulin using immunoblotting. B–C. Relative
expression of β1 (B) and β4 integrin (C) was calculated and normalized to tubulin. The level in control cells was set to 1. Data represent the
mean ± SEM (n = 3, * p<0.05 by two-sample t-tests). D–E. Total RNAs were isolated from PHLPP overexpressing Panc-1 cells (D) and
PHLPP knockdown ASPC-1 cells (E). Real-time PCR analysis was performed using probes specific for human β1 and β4 integrin genes.
Each experimental point was done in triplicates, and the graphs represent the mean ± SD (n = 3).

www.impactjournals.com/oncotarget
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ASPC-1 cells, and real-time PCR (RT-PCR) analysis was
performed using probes specific for the β4 or β1 integrin
gene. The results revealed that the mRNA levels of β4
and β1 integrin were not decreased by changes in PHLPP
expression (Figure 7D–7E). Interestingly, the levels of
β4 and β1 integrin mRNA were increased in PHLPP1β
overexpressing cells. However, since the expression of
β4 and β1 integrin proteins was decreased in PHLPP1β
overexpressing cells, this increase of integrin mRNA was
unlikely the reason for PHLPP-mediated downregulation
of integrin. Collectively, these results indicated that
PHLPP negatively regulates integrin expression via a posttranslational mechanism in pancreatic cancer cells.
To further investigate the mechanism by which
PHLPP regulates integrin expression, we tested if the
PI3K/Akt or the MEK/ERK pathway is involved in
controlling the expression of integrin proteins. Inhibiting
the PI3K/Akt pathway using a PI3K inhibitor, LY294002,
in ASPC-1 cells resulted in an approximately 40%
reduction in both β4 and β1 integrin expression over time
(Figure 8A–8B). A similar decrease of integrin expression
was seen in cells treated with an Akt inhibitor, Akt-VIII
(Supplementary Figure S3). However, treating cells with a
MEK inhibitor, PD325901, had no effect on the expression
of integrin (Supplementary Figure S3), suggesting that
PHLPP-induced downregulation of integrin is likely
mediated through inhibition of Akt signaling. As a
control, we found that the mRNA levels of integrin were
not significantly changed in cells treated with LY294002
(Supplementary Figure S3).
Recent studies have suggested that integrins can
be internalized upon binding to extracellular matrix
(ECM) ligands and trafficked to lysosome for degradation
[21–24]. To determine if decreased integrin expression
seen in PHLPP overexpressing cells is due to increased
lysosomal degradation, we incubated control and PHLPP
overexpressing Panc-1 cells in NH4Cl containing media.
The presence of NH4Cl, a lysosomotropic alkalinizing
agent, inhibits lysosomal protein degradation. At the end
of 8-hour treatment with NH4Cl, both β4 and β1 integrin
expression increased in response to lysosome inhibition
and the expression of integrin in PHLPP overexpressing
cells was similar to that of the control cells (Figure 8C).
Similar results were obtained in cells treated with a
different lysosome inhibitor, chloroquine (Supplementary
Figure S3). In addition, we determined if PHLPP promotes
integrin ubiquitination since ubiquitination has been linked
to lysosome-mediated degradation of integrin [21, 24].
Endogenous β4 and β1 integrin were immunoprecipitated
from control and PHLPP overexpressing Panc-1 cells,
and the ubiquitination levels of β4 and β1 integrin were
increased in both PHLPP1β and PHLPP2 overexpressing
cells (Figure 8D). Furthermore, since it has been shown
that activation of PI3K/Akt signaling promotes integrin
recycling to the plasma membrane by inhibiting GSK-3β
[25], we examined if PHLPP-mediated downregulation
www.impactjournals.com/oncotarget

of integrin can be rescued by inhibiting GSK-3 activity
directly. Indeed, when treating cells with LiCl, a
GSK-3 inhibitor, the expression of β1 and β4 integrin
increased in both control and PHLPP overexpressing
cells (Supplementary Figure S4). Taken together, our
results suggest that PHLPP may downregulate β4 and
β1 integrin expression by increasing the ubiquitination
of these proteins, and inhibition of lysosome-mediated
protein degradation rescues integrin expression in PHLPP
overexpressing cells.

Blocking integrin activity inhibits PHLPP-loss
induced increase in cell motility
To determine the functional impact of PHLPPmediated inhibition of integrin expression, we examined
the rate of cell migration in control and PHLPP
knockdown ASPC-1 cells in the presence of blocking
antibodies against β4 or β1 integrin. As shown in Figure
9A, incubating cells with either β4 or β1 integrin blocking
antibodies significantly reduced cell migration in both
control and PHLPP knockdown cells as measured by
Transwell assays. Moreover, inhibiting integrin activation
impaired cell motility at the single cell level as the
relative velocity in the control and PHLPP knockdown
cells became indistinguishable after the blocking antibody
treatment (Figure 9B). These data suggested that increased
integrin expression in PHLPP knockdown cells is
responsible for increased cell migration.

DISCUSSION
A number of recent studies have provided strong
evidence suggesting that PHLPP serves as an important
tumor suppressor in various cancer types [9, 10, 12, 15–
17, 26]. For example, it has been shown that PHLPP is
downregulated in colon cancer patients and decreased
PHLPP expression promotes tumor growth as the result
of increased activation of both PI3K/Akt and RAS/
RAF oncogenic signaling [12, 13, 15]. However, the
role of PHLPP in regulating cell migration has not
been determined in pancreatic cancer. Here we show
that PHLPP plays an important role in controlling cell
motility. Specifically, overexpression of either PHLPP
isoform decreases cell migration whereas knockdown of
endogenous PHLPPs significantly enhances cell motility
in pancreatic cancer cells. Moreover, the level of PHLPP
expression negatively regulates the ability of pancreatic
cancer cells to grow in 3D culture. This PHLPP-mediated
inhibition of cell growth and migration is coincided
with inhibition of both Akt and MEK/ERK activation.
Mechanistically, PHLPP inhibits β1 and β4 integrin
expression by increasing ubiquitination and lysosomemediated degradation of integrin proteins, and blocking
integrin activation reverses PHLPP-loss induced increase
in cell migration. Consistent with a previously published
7809
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Figure 8: Inhibition of PI3K/Akt pathway promotes lysosome-mediated integrin degradation. A. ASPC-1 cells were

incubated with LY294002 for 0–12 hours. At indicated time points, cell lysates were prepared and analyzed for the expression of β1 and β4
integrin and tubulin using immunoblotting. B. Relative expression levels of β1 and β4 integrin at different time points following LY294002
treatment in ASPC-1 cells were calculated and normalized to tubulin. The level in untreated cells was set to 1. Data represent the mean
± SEM (n = 3, * p<0.05 by two-sample t-tests). C. Stable control and PHLPP overexpressing Panc-1 cells were treated with NH4Cl (5
mM) for 2, 4, and 8 hours. Cell lysates were prepared and analyzed by immunoblotting for integrin expression. D. Cell lysates prepared
from stable control and PHLPP overexpressing Panc-1 cells were immunoprecipitated with antibodies against β1 or β4 integrin. The
ubiquitination of endogenous β1 and β4 integrin was detected using the anti-ubiquitin antibody.
www.impactjournals.com/oncotarget
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study [14], we find that overexpression of PHLPP isoforms
promote cell death but have little effect on proliferation in
PDAC cells (data not shown). Taken together, our findings
establish a novel link connecting PHLPP downregulation
with enhanced integrin function in pancreatic cancer.
The cell surface delivery and endocytosis of
integrins are dynamically regulated processes and
fundamental for cell migration in wound healing and

during cancer cell metastasis [27, 28]. Like many cell
surface receptors, integrins are known to undergo
endo/exocytic cycles, in which they are internalized,
trafficked through endosome, and then recycled back
to the plasma membrane [7, 28–30]. This recycle
process occurs rather efficiently as the degradation
rates of integrins are generally very slow [24, 31],
however, ligand-bound integrins can be ubiquitinated

Figure 9: The PHLPP-mediated regulation of cell migration relies on its ability to control integrin expression. A. Stable

control and PHLPP knockdown ASPC-1 cells were subjected to Transwell migration analysis using HGF as the chemoattractant. To block
integrin activation, ASPC-1 cell suspensions were incubated with blocking antibodies of β1 or β4 integrin in serum-free media containing
1% BSA for 20 minutes at 4 °C. The cells were then seeded onto the collagen coated Transwells in the presence of the blocking antibodies
and allowed to migrate for 4 hours at 37°C. Each experiment was done in duplicates and three independent experiments were averaged and
expressed as mean ± SEM (* p<0.01 by two-sample t-tests compared to the control cells). B. Cells as treated as above with blocking antibodies
were monitored for single cell motility using time-lapse imaging. The cells were allowed to migrate in response to HGF for 6 hours. The
average velocities of 12 cells from each group are shown. Data represent mean ± SEM (n = 12 cells/line, * p<0.05 by two-sample t-tests).
www.impactjournals.com/oncotarget
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EXPERIMENTAL PROCEDURES

and sorted to lysosome for degradation by the ESCRT
pathway [24, 32]. Our findings that overexpression of
PHLPP reduces the expression of β1 and β4 integrin
and enhances their ubiquitination suggest that PHLPP
may negatively control cell motility by inhibiting Akt
activity to promote lysosome-dependent degradation
of integrin. Since preventing lysosome-mediated
degradation of integrins increases recycling of integrins
to the plasma membrane and enhances integrinmediated cancer cell migration and invasion [29, 30],
PHLPP represents a novel regulator of cell motility
by controlling the balance of integrin recycling and
degradation in pancreatic cancer cells.
Previous studies have shown that the protein
expression of both PHLPP isoforms are reduced in
pancreatic cancer patient specimens compared to normal
pancreases tissues [14]. We have interrogated the mRNA
expression of PHLPP in several gene expression databases
and found that the expression of PHLPP1 is significantly
decreased in pancreatic tumor samples compared to normal
samples whereas PHLPP2 mRNA expression is less
affected (Supplementary Figure S5). Thus, loss of PHLPP
protein expression in pancreatic cancer is likely mediated
via a post-transcriptional or post-translational mechanism.
Interestingly, recent studies have identified PHLPP2 as a
bona fide target for a number of oncogenicmicroRNAs
(miRNAs), including miR-372, miR-224 and miR-17~92,
in difference cancer types [33–35]. In addition, single
nucleotide variations in both PHLPP genes are rare (<1%
based on COSMIC collections of somatic mutations).
Future studies are needed to determine the mechanism
leading to downregulation of PHLPP proteins.
Due to the late stage diagnosis and the aggressive
nature of the carcinoma itself, PDAC patients have a very
low survival rate [1, 4]. The treatment options for PDAC
are few and surgical resection is nearly impossible for
the average patient [36]. Understanding the molecular
mechanism leading to EMT and progression of PDAC
potentially has a long lasting benefit in creating
new treatment strategies. In this study, we provide
strong evidence supporting a tumor suppressor role
of PHLPP in pancreatic cancer. Moreover, our finding
that decreased PHLPP expression promotes EMT and
cell motility through inhibiting lysosome degradation
of integrin proteins identifies a novel mechanism by
which PHLPP suppresses oncogenic signaling. Recent
studies have demonstrated that upregulation of β4
integrin is associated with the EMT phenotype and poor
prognosis in pancreatic cancer [37] and increased β1
integrin expression in tamoxifen-resistant breast cancer
cells promotes EMT [38]. Future studies are needed
to determine if PHLPP-loss induced EMT requires
upregulation of integrin in PDAC cells. Collectively,
our study highlights the importance of further exploring
PHLPP as a possible diagnostic marker for targeted
therapy in pancreatic cancer.
www.impactjournals.com/oncotarget

Cells and reagents
The following pancreatic ductal adenocarcinoma
cell lines, including ASPC-1, Panc-1, and Suit-2, were
kindly provided by Dr. Kathleen O’Connor (University
of Kentucky). The Panc-1 cells used in this study were
sorted for their high integrin expression as described
previously [6]. Panc-1 cells were cultured in DMEM
whereas ASPC-1 cells were cultured in RPMI-1640. All
media were supplemented with 10% fetal bovine serum
(FBS, Sigma-Aldrich) and 1% penicillin/streptomycin.
The shRNAs used to knockdown human PHLPP1 or
PHLPP2 gene and the retroviral expression plasmids,
including pBabe-puro-HA-PHLPP1β and pBabepuro-HA-PHLPP2, have been described previously
[13, 15]. The stable PHLPP overexpressing cells were
generated by infecting cells with retrovirus encoding
HA-PHLPP1β or HA-PHLPP2 and selecting with
puromycin (1 μg/ml).
The PHLPP1 and PHLPP2 antibodies were
obtained from Proteintech and Bethyl Laboratories,
respectively. The phospho-Akt (p-Akt for the Ser473
site), phospho-ERK1/2 (p-ERK for Thr202/Tyr204),
phospho-MEK1/2 (p-MEK for Ser217/221), and
E-cadherin antibodies were from Cell Signaling. The
vimentin antibody was from BD Biosciences, the g
tubulin antibody was from Sigma-Aldrich, and the
ubiquitin antibody was from Santa Cruz Biotechnology.
The following integrin antibodies were used in this
study: for Western blotting, anti-β1 rabbit mAb (D2E5,
Cell Signaling) and anti-β4 mouse mAb (clone 7, BD
Biosciences); and for blocking ECM binding and
immunoprecipitation, anti-β1 mouse mAb (clone
6S6, Millipore) and anti-β4 mouse mAb (clone ASC8, Millipore). The following chemicals, including
PI3K inhibitor LY290042 and Akt inhibitor VIII, were
purchased from EMD/CalBiochem. The MEK1/2
inhibitor PD0325901 was purchased from Selleck
Chemicals, and lysosome inhibitor chloroquine was from
Sigma-Aldrich.

Immunoblotting
Cultured cells were harvested and lysed in Lysis
Buffer (50 mM Na2HPO4, 1 mM sodium pyrophosphate,
20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton
X-100, 1 mM DTT, 200 mM benzamidine, 40 mg ml-1
leupeptin, 200 mM PMSF) and the detergent-solublized
cell lysates were obtained after centrifugation for 5
minutes at 16,000 g at 4 oC. Equal amounts of cell lysates
as determined by Bradford assays were resolved by SDSPAGE and subjected to immunoblotting analysis. The
density of ECL signals was obtained and quantified using
a FluoChem digital imaging system (Alpha Innotech).
7812
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Transwell migration assays

Statistical analysis

Serum starved pancreatic cancer cells were seeded
into the upper chamber of Transwell inserts with an 8-mm
pore size membrane (Corning). For migration assays, the
bottom of the inserts were coated with collagen (15 mg/
ml) or laminin (25 μg/ml), and the cells were allowed to
migrate towards media containing either HGF (20 ng/ml)
or IGF (20 ng/ml) in the lower chamber for 2-5 hours. At
the end of the incubation period, Transwell inserts were
fixed in methanol and stained with 0.5% crystal violet.
The numbers of cells that were migrated to the lower
chamber of the Transwell were counted using an inverted
microscope at 20X magnification.

Normalized microarray and patient clinical
data from two pancreatic cancer studies [39, 40] were
downloaded from the Oncomine database. The Badea et
al data [40] contain matched tumor and normal samples
from 36 pancreatic cancer patients. The TCGA data [39]
contain tumor samples from 65 pancreatic cancer patients
and normal samples from 65 patients, within which 64
patients have both tumor and normal samples. Expression
levels of multiple probes mapping to the same gene were
averaged. Gene expressions from replicated tumor or
normal samples for the same patient were also averaged.
The paired t-test or linear mixed model was used to
compare PHLPP1 and PHLPP2 expressions between
tumor and normal samples.

Time-lapse live cell imaging and analysis
Stable control and PHLPP overexpressing Panc-1
cells and PHLPP knockdown ASPC-1 cells were serum
starved for 2 hours and seeded as single cells onto collagen
(15 mg/ml) or laminin (25 mg/ml) coated glass bottom
culture dishes (MatTek). The migration of live cells was
recorded in media containing HGF (20 ng/ml) using Nikon
BioStation IM equipped with CO2 incubation chamber.
Time-lapse phase images were taken either every 5 or 10
minutes for 6 hours with a 20X objective. The movement
of cells was tracked and analyzed using Nikon Element
AR software.
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